CAC vs Other Cardiac Tests

Introduction

Multiple tests exist for evaluating cardiovascular risk and detecting coronary artery disease. Each one answers a different question. Choosing among them depends on whether you are trying to identify subclinical disease in someone without symptoms, evaluate the cause of chest pain, or guide treatment intensity for someone with known risk factors.

CAC scoring excels at detecting atherosclerosis years before it causes symptoms and predicting long-term event risk. CT angiography reveals detailed anatomy including non-calcified plaque and stenosis severity. Stress tests assess whether existing disease limits blood flow under exertion. Traditional risk calculators estimate probability using clinical variables but cannot see actual disease. Understanding these distinctions helps patients and clinicians select the right test for the right question.

This article compares CAC to the major alternatives: CT angiography, stress testing, clinical risk calculators, carotid imaging, and biomarkers. For guidance on acting on CAC results, see What to Do With Your CAC Results. For information on CAC limitations, see Limitations and Controversies of CAC Scoring.

How does a CAC scan compare to a CT angiogram in terms of information provided?

A CAC scan is a non-contrast study that detects and quantifies calcium. A CT angiogram (CCTA) uses intravenous contrast to visualize the arterial lumen, assess stenosis severity, and characterize plaque composition including non-calcified components. The CAC scan answers whether atherosclerosis exists and how much calcium has accumulated. The CCTA answers whether any lesions significantly narrow the artery.

Studies comparing the two modalities in young symptomatic patients found that CCTA detected coronary artery disease in 46% of patients with zero calcium, highlighting CAC’s blind spot for non-calcified plaque (Feuchtner et al., 2021). CCTA requires more radiation, contrast injection, and typically costs more. It is the appropriate test when symptoms suggest obstructive disease or when detailed anatomic information will guide management.

CAC provides sufficient information for primary prevention screening in asymptomatic individuals. The goal is to detect subclinical atherosclerosis and refine risk estimates, not to diagnose obstructive lesions. Reserving CCTA for situations where anatomic detail matters avoids unnecessary contrast exposure and cost.

When is a CAC scan sufficient, and when should you push for a CT angiogram?

A CAC scan is sufficient when the primary question is whether subclinical atherosclerosis exists and how aggressively to pursue prevention. Asymptomatic individuals seeking risk stratification, those deciding whether to start statin therapy, or people with intermediate calculated risk are reasonable candidates for CAC alone.

CCTA becomes appropriate when symptoms suggest angina, when a zero CAC score coexists with concerning clinical features, or when treatment decisions require knowledge of stenosis severity. Research shows that adding CCTA to CAC scoring in patients with low clinical likelihood of disease improves management decisions, particularly by excluding obstructive disease (Brix, 2024).

The choice also depends on downstream implications. If a positive CAC would simply reinforce lifestyle modifications and statin therapy, the additional information from CCTA may not change management. If the result would influence decisions about invasive testing or revascularization, the anatomic detail from CCTA becomes more valuable.

How does CAC scoring compare to stress testing for detecting heart disease?

CAC scoring detects atherosclerotic plaque directly. Stress testing assesses whether coronary blood flow is adequate during increased demand. A stress test can be normal despite significant plaque if the narrowing does not limit flow. Conversely, microvascular disease can cause abnormal stress tests without epicardial stenosis.

Comparative studies have shown that coronary CTA and stress echocardiography provide complementary information for predicting cardiac outcomes. CAC and anatomic imaging detect disease presence, while functional tests assess its physiological significance (Gaibazzi, 2023). Both approaches have independent prognostic value.

For asymptomatic screening, CAC is preferred because it identifies disease years before it becomes flow-limiting. For evaluating symptoms that might represent angina, stress testing or CCTA may be more appropriate as first-line tests. Guidelines generally recommend against stress testing for asymptomatic individuals without known disease.

What can a CAC scan tell you that traditional risk calculators cannot?

Risk calculators like the Framingham Risk Score and Pooled Cohort Equations estimate 10-year cardiovascular event probability based on age, sex, blood pressure, cholesterol, smoking, and diabetes. They predict population-level risk but cannot determine whether any individual has developed disease. Two people with identical calculated risk may have vastly different actual atherosclerotic burden.

The CAC Consortium study demonstrated that CAC provides risk information beyond traditional factors. Among individuals calculated to be at intermediate risk, those with CAC of zero had low event rates, while those with high CAC had event rates typical of established disease (Grandhi, 2020). CAC reclassifies many patients into more appropriate risk categories.

Research confirms that adding CAC to Framingham scores substantially improves prediction of coronary events (Church, 2007). The improvement is greatest for those at intermediate calculated risk, where CAC often shifts management decisions about statin therapy and prevention intensity.

How does CAC compare to carotid intima-media thickness testing?

Carotid intima-media thickness (CIMT) measures arterial wall thickness in the neck using ultrasound. Like CAC, it aims to detect subclinical atherosclerosis. However, CIMT has more measurement variability and weaker predictive value than CAC. Professional societies no longer recommend CIMT for routine risk assessment.

CAC provides direct visualization of coronary atherosclerosis, the exact location where most cardiovascular events originate. CIMT measures a surrogate in a different vascular bed. While carotid disease correlates with coronary disease, the relationship is imperfect. A person can have significant coronary calcium with minimal carotid thickening or vice versa.

The practical advantage of CAC is that the coronary arteries themselves are being evaluated. The Agatston score has been validated across millions of patients in multiple ethnic groups with consistent predictive performance. CIMT lacks this level of validation and standardization.

What’s the role of CAC relative to biomarkers like Lp(a), ApoB, or hsCRP?

Biomarkers and CAC answer different questions. Lp(a) and ApoB measure circulating particles that drive atherosclerosis. High-sensitivity C-reactive protein (hsCRP) reflects systemic inflammation. These tests indicate mechanisms and risk factors. CAC measures the disease that has actually developed in the coronary arteries.

A person with elevated Lp(a) may have a zero CAC score if they are young or if their atherosclerosis has not yet calcified. Conversely, someone with optimal lipid levels may have substantial CAC from prior exposure before treatment began. Biomarkers guide therapy targets, while CAC confirms whether disease has developed despite or because of those biomarker levels.

Optimal assessment often includes both approaches. Biomarkers identify treatable drivers that warrant intervention. CAC reveals whether prevention efforts are succeeding at the tissue level. Guidelines support using CAC to inform treatment decisions, particularly in patients whose biomarkers are elevated but who remain undecided about therapy intensity.

Why might a doctor recommend one test over another?

Clinical context determines the appropriate test. For an asymptomatic 50-year-old with borderline lipids and intermediate calculated risk, CAC provides the most useful information: is there disease, and should we treat aggressively? The result directly informs statin therapy decisions.

For a 60-year-old with exertional chest pressure, functional testing or CCTA makes more sense. The question is whether obstructive disease explains the symptoms, not whether subclinical atherosclerosis exists. A high CAC score in this patient would not answer the clinical question.

Economics also plays a role. Stress tests and risk calculators are often covered by insurance. CAC scanning is frequently not covered for asymptomatic screening. Some physicians recommend tests based on what insurers will pay rather than what provides optimal information. Understanding these dynamics helps patients advocate for appropriate testing, which is addressed in How to Get a CAC Scan If Your Doctor Doesn’t Suggest One.

Conclusion

CAC scoring occupies a specific niche: detecting subclinical coronary atherosclerosis and stratifying long-term risk in asymptomatic individuals. It does not replace CT angiography for evaluating symptoms, stress testing for assessing ischemia, or biomarkers for guiding lipid therapy. Each test answers a different question.

For primary prevention decision-making, CAC often provides the most actionable information. A zero score is reassuring. A high score demands attention. The result directly informs whether aggressive prevention is warranted. Understanding how CAC compares to alternatives positions patients to request the right test for their situation.

The next step is translating CAC results into action. For guidance on treatment decisions, see What to Do With Your CAC Results. For information on who should be screened, see Who Should Get a CAC Scan?.